Metoclopramide Orifarm

Metoclopramide, the active ingredient in Metoclopramide Orifarm, is a dopamine antagonist (antiemetic, gastro‑prokinetic) presented as an oral dosage form for systemic use. It is indicated for use in patients experiencing acute or chronic nausea, for those with delayed gastric emptying, and as a prophylactic agent before chemotherapy.\n\nGNH India supplies Metoclopramide Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways of the gastrointestinal system and the central chemoreceptor trigger zone to control several conditions.\n\n- Nausea and vomiting: reduces frequency and severity of episodes in various settings.\n- Gastroparesis: enhances gastric emptying and relieves associated symptoms.\n- Gastro‑oesophageal reflux disease (GERD): decreases reflux episodes and improves patient comfort.\n- Chemotherapy‑induced nausea: prevents or lessens nausea associated with anticancer treatment.

Metoclopramide may cause a range of adverse reactions, which are classified by frequency and severity.\n\nCommon Side Effects:\n- Drowsiness: feeling of sleepiness or reduced alertness.\n- Fatigue: general tiredness or lack of energy.\n- Restlessness: uneasy feeling often described as akathisia.\n- Dry mouth: reduced salivation leading to throat discomfort.\n\nSerious or Rare Side Effects:\n- Extrapyramidal symptoms: involuntary muscle movements or rigidity.\n- Tardive dyskinesia: persistent, potentially irreversible facial or tongue movements.\n- Neuroleptic malignant syndrome: rare life‑threatening reaction with fever and muscle rigidity.\n- Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Metoclopramide, clinicians should consider several precautionary measures to ensure safe use.\n\n- Assess renal and hepatic function: adjust use in patients with impairment.\n- Monitor for extrapyramidal symptoms: watch for muscle rigidity or tremor.\n- Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs.\n- Use caution in the elderly: increased susceptibility to CNS effects.\n- Limit duration of therapy: prolonged use raises risk of tardive dyskinesia.\n- Store at below 25°C: keep in the original packaging, protect from moisture.

Metoclopramide can interact with other medicines, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Antipsychotics (e.g., haloperidol): may counteract antiemetic effect.\n- Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis.\n- Central nervous system depressants (e.g., opioids): enhance sedation and respiratory depression.\n\nModerate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise metoclopramide plasma levels.\n- Anticholinergic agents: may reduce pro‑kinetic benefit.\n- Selective serotonin reuptake inhibitors (SSRIs): potential for additive serotonergic effects.